Allay Therapeutics

Allay Therapeutics company information, Employees & Contact Information

Allay Therapeutics is pioneering ultra-sustained analgesic products to transform post-surgical pain management and recuperation for patients and physicians. We believe an era of stalled innovation for pain management is over. From San Francisco to Singapore, our team has a passion for solving medical challenges that could benefit millions. We pursue our mission with the energy of a dynamic, global team of entrepreneurs, scientists, clinicians and innovators.

Company Details

Employees
52
Founded
-
Address
2720 Zanker Rd, San Jose,california 95134,united States
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
HQ
San Jose, California
Looking for a particular Allay Therapeutics employee's phone or email?

Allay Therapeutics Questions

News

Allay Therapeutics Announces Expansion of Clinical and Scientific Advisory Boards to Support the Company’s Mission to Transform Post-Surgical Pain Management - Business Wire

Allay Therapeutics Announces Expansion of Clinical and Scientific Advisory Boards to Support the Company’s Mission to Transform Post-Surgical Pain Management Business Wire

Allay Therapeutics Announces Development and Commercialization Agreement with Maruishi Pharmaceutical for Ultra-Sustained Pain Therapeutics in Japan - The AI Journal

Allay Therapeutics Announces Development and Commercialization Agreement with Maruishi Pharmaceutical for Ultra-Sustained Pain Therapeutics in Japan The AI Journal

Allay Therapeutics Announces First Patients Dosed in Pivotal Phase 2b Registration Trial of ATX101 for Post-Surgical Pain Management After Knee Replacement Surgery - Business Wire

Allay Therapeutics Announces First Patients Dosed in Pivotal Phase 2b Registration Trial of ATX101 for Post-Surgical Pain Management After Knee Replacement Surgery Business Wire

Allay Therapeutics Announces $57.5M Series D Financing and Venture Debt Line to Advance ATX101 and its Ultra-Sustained Pain Platform for Post-Surgical Pain Management - Business Wire

Allay Therapeutics Announces $57.5M Series D Financing and Venture Debt Line to Advance ATX101 and its Ultra-Sustained Pain Platform for Post-Surgical Pain Management Business Wire

ClavystBio launches to translate life sciences breakthroughs into health impact - en.prnasia.com

ClavystBio launches to translate life sciences breakthroughs into health impact en.prnasia.com

Allay Therapeutics Receives FDA Breakthrough Therapy Designation (BTD) for ATX101 for the Treatment of Post-surgical Pain Following Total Knee Replacement Surgery - Business Wire

Allay Therapeutics Receives FDA Breakthrough Therapy Designation (BTD) for ATX101 for the Treatment of Post-surgical Pain Following Total Knee Replacement Surgery Business Wire

Allay Therapeutics Completes Oversubscribed $60M Financing to Advance Ultra-Sustained Pain Platform - Business Wire

Allay Therapeutics Completes Oversubscribed $60M Financing to Advance Ultra-Sustained Pain Platform Business Wire

Top Allay Therapeutics Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant